ATL Webcast to Address Considerations in Selecting a Laboratory Information Management System (LIMS)
News Feb 07, 2014
Accelerated Technology Laboratories, Inc. (ATL) will host the second in a series of complimentary webcasts on Wednesday, February 19, 2014, to share information on Considerations in Selecting a LIMS. This informative webinar will feature key points to consider in the selection of a LIMS, and offers attendees a complimentary copy of ATL's LIMS Roadmap to Success Guide, which provides helpful suggestions, from LIMS selection through deployment.
Data automation will help organizations maximize resources and strengthen overall performance by streamlining operations. Organizations are increasingly required to improve reporting and audit trails, along with efficiency, to counter a decrease in resources. Implementing a LIMS will enhance data quality and reduce transcription errors with instrument integration, provide for charting of historical data, boost competitive advantage and assist in meeting regulatory compliance (FDA, cGMP, EPA, SQF etc.) goals. Added benefits of investing in a LIMS include standardization across organizational spectrums, an increase in resource utilization efficiency and higher profitability.
Recommended attendees include laboratory owners, directors and managers, and quality managers and directors in the analytical, food & beverage, manufacturing (product/material testing), agriculture, energy, environmental, water/wastewater, life science, pharmaceutical, biotechnology, and public health sectors.
DATE: Wednesday, February 19, 2014
TIME: 1:00PM-1:30PM US Eastern Time
12:00PM - 12:30PM US Central Time
11:00AM - 11:30PM US Mountain Time
10:00AM - 10:30AM US Pacific Time
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE